<DOC>
	<DOCNO>NCT01859923</DOCNO>
	<brief_summary>The purpose trial ass safety , tolerability , pharmacokinetics , efficacy long-term ( 6-month ) treatment delamanid plus optimized background regimen anti-tuberculosis drug pediatric patient complete Trial 242-12-232 .</brief_summary>
	<brief_title>A 6-Month Safety , Efficacy , PK Trial Delamanid Pediatric Patients With Multidrug Resistant Tuberculosis</brief_title>
	<detailed_description>This phase 2 , open-label , multiple-dose , multicenter trial ass safety , tolerability , pharmacokinetics , efficacy delamanid plus optimized background regimen pediatric patient MDR-TB 6-month treatment period . This long-term trial , extension Trial 242-12-232 , conduct patient complete Trial 232 . Enrollment complete patient Groups 1 , 2 , 3 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<criteria>Successfully complete Trial 24212232 Confirmed diagnosis MDRTB OR Presumptive diagnosis pulmonary extrapulmonary MDRTB include one following : Clinical specimen suggestive tuberculosis disease Persistent cough lasting &gt; 2 week Fever , weight loss , failure thrive Findings recent chest radiograph ( prior Visit 1 ) consistent TB AND Household contact person know MDRTB person die appropriately take drug sensitive TB OR On firstline TB treatment clinical improvement Negative urine pregnancy test female patient reach menarche Written inform consent/assent Patients complete Trial 24212232 Laboratory evidence active hepatitis B C Children body weight &lt; 5.5 kg For patient HIV coinfection , CD4 cell count ≤ 1000/mm3 child 15 year old , ≤ 1500/mm3 child less 1 year old History allergy metronidazole disease condition metronidazole require Use amiodarone within 12 month use predefined antiarrhythmic medication within 30 day prior first dose delamanid Serious concomitant condition Preexisting cardiac condition Abnormalities Screening ECG ( include AV block , BBB hemiblock , QRS prolongation &gt; 120 msec , QTcF &gt; 450 msec male female ) Concomitant condition renal impairment characterize serum creatinine level &gt; 1.5 mg/dL , hepatic impairment ( ALT AST &gt; 3x ULN ) , hyperbilirubinemia characterize total bilirubin &gt; 2x ULN Current diagnosis severe malnutrition kwashiorkor Positive urine drug screen ( Groups 1 2 ) Rifampicin and/or moxifloxacin within 1 week prior first dose delamanid and/or prior concurrent use bedaquiline Lansky Play Performance Score &lt; 50 ( applicable child &lt; 1 year old ) Karnofsky Score &lt; 50 Administered IMP within 1 month prior Visit 1 delamanid give IMP Trial 24212232 Pregnant , breastfeeding , plan conceive father child within timeframe describe informed consent form ( Groups 1 2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Tuberculosis , Multidrug-Resistant</keyword>
	<keyword>Mycobacterium Infections</keyword>
	<keyword>Actinomycetales Infections</keyword>
	<keyword>Gram-Positive Infections</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Pediatric</keyword>
</DOC>